To include your compound in the COVID-19 Resource Center, submit it here.

Heartfelt WISPER

HaYa's ASOs target WISPER for safer treatment of cardiac fibrosis

HaYa Therapeutics is using antisense oligonucleotides to target the lncRNA WISPER to treat cardiac fibrosis caused by cardiovascular diseases such as myocardial infarction. Because WISPER expression is confined to the heart, the newco is betting its ASOs will have fewer off-target effects in non-cardiac tissues than other therapies in development for cardiac fibrosis.

The newco's WISPER program evolved from research into long

Read the full 615 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE